Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study
Open Access
- 31 October 2016
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 184, 81-87
- https://doi.org/10.1016/j.ahj.2016.10.017
Abstract
No abstract availableFunding Information
- Bayer
- Janssen Pharmaceuticals
This publication has 30 references indexed in Scilit:
- Aortic Stenosis in the ElderlyJournal of the American College of Cardiology, 2013
- Histopathology of Embolic Debris Captured During Transcatheter Aortic Valve ReplacementCirculation, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Dual Antiplatelet Therapy Versus Aspirin Alone in Patients Undergoing Transcatheter Aortic Valve ImplantationThe American Journal of Cardiology, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation, 2011
- Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk PatientsNew England Journal of Medicine, 2011
- Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo SurgeryNew England Journal of Medicine, 2010
- Idraparinux versus Standard Therapy for Venous Thromboembolic DiseaseNew England Journal of Medicine, 2007